Corpovael S.A.B. de C.V (CADUA) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Corpovael S.A.B. de C.V stock MXN 20.97, price MXN 6.99, upside +200.0%, quality 67 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.
How to read this chart
60‑month range 1.52 MXN – 7.89 MXN · fair‑value band 14.68 MXN – 27.26 MXN · the 6.99 MXN price screens below the 20.97 MXN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.
Follow Corpovael S.A.B. de C.V in your weekly email
Every Wednesday you see whether Corpovael S.A.B. de C.V is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Corpovael, S.A.B. de C.V. engages in the design, urbanization, construction, promotion, and sale of homes in Mexico. The company develops social interest, middle-class, middle-residential, and residential housing. Corpovael, S.A.B. de C.V. was founded in 2001 and is based in Cancun, Mexico.
Stock analysis
Corpovael S.A.B. de C.V (CADUA) currently trades at 6.99 MXN, while our model-based Fair Value estimate is 20.97 MXN, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 25.92 MXN per share, and 23 of the 26 models we run sit above the 6.99 MXN price.
Bear case: the Dividend Discount group reads lowest at 9.01 MXN, and 3 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 14.68 MXN (bear) to 27.26 MXN (bull), the price of 6.99 MXN sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Real Estate sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Corpovael S.A.B. de C.V reported revenue of 5.1B MXN in FY2025 versus 2.8B MXN in FY2021, a compound +16.2%/yr. Reported net income was 412M MXN in FY2025.
Key figures
Market cap 2.0B MXN (≈ $110M) Micro · P/E ratio 4.7 · P/S ratio 0.34 · EPS (TTM) 1.50 MXN · Dividend yield 5.4% · Net margin 7.4% · Return on equity 7.6% · Return on assets (EBIT) 3.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 73% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Real Estate peers we cover trades at −4% fair-value upside, at 200%, CADUA screens cheaper than that median.
Fair Value models
Bear14.68 MXNFair Value 20.97 MXNBull27.26 MXN
Price 6.99 MXN · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.9758 MXN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.78/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Start year 2020 (pandemic). Over 10 years: +3.7% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MXN ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in MXN: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +23.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +17.7%
Dividend (yield on the price)5.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 7.4% / −1.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 9%
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 0.71 per share, median 2.71 in 2016 to 2018). It measures the recovery from the trough, not lasting growth.
⚠ Rate on operating basis: 2025 sits 74% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−13.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Mexico: IMF forecast 3.3% a year to 2030, 4.8% from 2016 to 2025) that is about −15.7% a year for the price.
Compare Corpovael S.A.B. de C.V with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Real Estate - Development · 492 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)7.6% · Above median
Return on assets3.5% · Above median
Net margin (12 months)7.4% · Below median
Operating margin (12 months)11.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)34.0% · Top 25%
Dividend yield (12 months)5.4% · Above median
Balance sheet
Debt / equity0.25× · Below median
Valuation Multiplesvs Real Estate - Development median · lower = cheaper
P/E (12 months)4.7× · Cheapest 25%
P/B0.35× · Cheapest 25%
P/S (12 months)0.34× · Cheapest 25%
Price / free cash flow (fiscal year)2.4× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Corpovael S.A.B. de C.V Fair Value". https://www.fairvalue-calculator.com/stock/CADUA
Frequently asked questions
Is Corpovael S.A.B. de C.V (CADUA) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of 20.97 MXN versus a price of 6.99 MXN, about +200% upside (undervalued).
What is the fair value of CADUA?
Our model-based fair value for Corpovael S.A.B. de C.V is 20.97 MXN (as of Nov 13, 2026), built from audited fundamentals. The current price: 6.99 MXN.
What is the quality score of CADUA?
Corpovael S.A.B. de C.V has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Corpovael S.A.B. de C.V (CADUA)?
Our model-based price target is the fair value of 20.97 MXN (as of Nov 13, 2026) from 26 valuation models. Cautious scenario 14.68 MXN, optimistic scenario 27.26 MXN. It is a calculation from audited fundamentals, not an analyst target.
What is the Corpovael S.A.B. de C.V stock forecast for 2026?
Our models put fair value at 20.97 MXN, about +200% upside versus a price of 6.99 MXN (undervalued). Cautious scenario 14.68 MXN, optimistic scenario 27.26 MXN. The calculation is refreshed regularly with new filings.
What is the revenue of Corpovael S.A.B. de C.V (CADUA)?
Corpovael S.A.B. de C.V reported trailing-twelve-month revenue of about 6.0B MXN (latest available figure, as of Nov 13, 2026).
Does Corpovael S.A.B. de C.V pay a dividend?
Corpovael S.A.B. de C.V currently shows a dividend yield of 5.44% relative to its recent price (as of Nov 13, 2026).
How much is the dividend of Corpovael S.A.B. de C.V (CADUA) and when is the ex-dividend date?
Corpovael S.A.B. de C.V pays a dividend of 0.38 MXN per share a year, a dividend yield of 5.4%. The last ex-dividend date was Aug 27, 2026. The payout ratio is 25.3% of earnings. Free cash flow covers the dividend 7.72 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Corpovael S.A.B. de C.V (CADUA)?
For today's price to be fair in a discounted-cash-flow model, Corpovael S.A.B. de C.V would have to grow free cash flow by -13.0 % per year for five years (discount rate 15.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.0 % per year. As of Nov 13, 2026.
What discount rate (WACC) does the fair value of CADUA use?
Our models discount Corpovael S.A.B. de C.V at 15.0 %: a base by market capitalisation (micro), country premium for Mexico. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Corpovael S.A.B. de C.V that is -13.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.0 %) and the same formula as our fair value.
How much growth has Corpovael S.A.B. de C.V (CADUA) delivered so far?
Over the past 5 years revenue at Corpovael S.A.B. de C.V grew +9.0 % a year. The price currently implies free-cash-flow growth of -13.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Corpovael S.A.B. de C.V (CADUA) growing?
The median revenue growth in the sector is +4.5 % a year. That is the yardstick for the growth priced into Corpovael S.A.B. de C.V (-13.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Corpovael S.A.B. de C.V (CADUA)?
The free-cash-flow yield on the price is 41.98 %: that much free cash flow Corpovael S.A.B. de C.V produces per unit of market value. When it exceeds the discount rate of our models (15.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Corpovael S.A.B. de C.V (CADUA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Corpovael S.A.B. de C.V it is 20.97 MXN per share (as of Nov 13, 2026), against a price of 6.99 MXN. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Corpovael S.A.B. de C.V stock overvalued or undervalued in 2026?
As of Nov 13, 2026, CADUA trades below its calculated fair value: price 6.99 MXN, fair value 20.97 MXN, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CADUA?
No. The price is what the market pays today (6.99 MXN); the fair value is what the company's own numbers justify (20.97 MXN). For Corpovael S.A.B. de C.V the two are 13.98 MXN per share apart. That gap is exactly why we show both numbers side by side.
How much is Corpovael S.A.B. de C.V worth?
The market values Corpovael S.A.B. de C.V at about 2.0B MXN (market capitalisation, as of Nov 13, 2026). Per share that is 6.99 MXN; our models calculate a fair value of 20.97 MXN per share.
What do the bullish and bearish scenarios say about CADUA?
Our models span a range for Corpovael S.A.B. de C.V: cautious scenario 14.68 MXN, base 20.97 MXN, optimistic 27.26 MXN per share (as of Nov 13, 2026, price 6.99 MXN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CADUA?
Corpovael S.A.B. de C.V trades at a price-to-earnings ratio of 4.7 (as of Nov 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 20.97 MXN is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 4.7. Other multiples: P/B 0.4, P/S 0.3, EV/EBITDA 4.9.
How solid is the balance sheet of Corpovael S.A.B. de C.V (CADUA)?
Balance-sheet figures for Corpovael S.A.B. de C.V (as of Nov 13, 2026): return on equity 7.6%, debt of 0.25 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is CADUA from its 52-week high?
Corpovael S.A.B. de C.V trades at 6.99 MXN, about 11% below its 52-week high of 7.89 MXN and 73% above the low of 4.05 MXN (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of 20.97 MXN is for.
Which stocks are comparable to Corpovael S.A.B. de C.V?
From the same area (Real Estate) we also value Sun Hung Kai Properties Limited, CK Asset Holdings, DLF Limited, Hongkong Land Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Corpovael S.A.B. de C.V stock attractive at the current price?
The data as of Nov 13, 2026: price 6.99 MXN, calculated fair value 20.97 MXN (+200%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CADUA calculated?
We run Corpovael S.A.B. de C.V through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 20.97 MXN builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Corpovael S.A.B. de C.V currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Corpovael S.A.B. de C.V (CADUA)?
The closing price on Nov 13, 2026 was 6.99 MXN. Our model-based fair value is 20.97 MXN, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Corpovael S.A.B. de C.V right now?
The price is below even our cautious bear case (14.68 MXN). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (14.68 MXN to 27.26 MXN) leaves room in how you read the outcome.
Key figures of Corpovael S.A.B. de C.V
How large is the market capitalisation of Corpovael S.A.B. de C.V (CADUA)?
The market capitalisation of Corpovael S.A.B. de C.V is 2.0B MXN (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Corpovael S.A.B. de C.V (CADUA)?
The price-to-sales ratio of Corpovael S.A.B. de C.V is 0.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Corpovael S.A.B. de C.V (CADUA)?
Earnings per share at Corpovael S.A.B. de C.V are 1.50 MXN (price ÷ EPS = P/E 4.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Corpovael S.A.B. de C.V (CADUA)?
The dividend yield of Corpovael S.A.B. de C.V is 5.4% (payout 25.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Corpovael S.A.B. de C.V (CADUA)?
The net margin of Corpovael S.A.B. de C.V is 7.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Corpovael S.A.B. de C.V (CADUA)?
The return on equity (ROE) of Corpovael S.A.B. de C.V is 7.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Corpovael S.A.B. de C.V (CADUA)?
On an EBIT basis the return on assets of Corpovael S.A.B. de C.V is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Corpovael S.A.B. de C.V (CADUA)?
The operating margin of Corpovael S.A.B. de C.V is 11.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Corpovael S.A.B. de C.V (CADUA)?
Revenue at Corpovael S.A.B. de C.V is growing +34.0% versus a year earlier (3y avg +10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Corpovael S.A.B. de C.V (CADUA)?
Earnings per share at Corpovael S.A.B. de C.V are growing +21.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Corpovael S.A.B. de C.V (CADUA) carry?
The net debt of Corpovael S.A.B. de C.V is 1.2B MXN (fiscal year 2025, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Corpovael S.A.B. de C.V in the live analysis
One click puts Corpovael S.A.B. de C.V on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 13, 2026